Skip to main content

Drug metabolites can now be patented

HOUSTON Bristol-Myers Squibb Company unveiled both a scientific achievement and a patent strategy that, if used by other drug companies, could delay introduction of cheaper generic versions of hundreds of patented drugs. Typically, after patents expire and generic versions of a drug become available, most drugs lose up to 80% of sales during the first year they face generic competition, according to Barbara Ryan, a drug industry analyst with Deutsche Banc Alex Brown. US patents on drugs with sal

Written byJohn Borchardt
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

HOUSTON Bristol-Myers Squibb Company unveiled both a scientific achievement and a patent strategy that, if used by other drug companies, could delay introduction of cheaper generic versions of hundreds of patented drugs. Typically, after patents expire and generic versions of a drug become available, most drugs lose up to 80% of sales during the first year they face generic competition, according to Barbara Ryan, a drug industry analyst with Deutsche Banc Alex Brown. US patents on drugs with sales approaching $20 billion annually will expire over the next five years.

The Bristol-Myers Squibb (BMS) strategy was to identify the pharmacologically active metabolites produced by patients taking the widely used anti-anxiety medication BuSpar (buspirone HCl). The scientific achievement was to identify a metabolite, 6-hydroxybuspirone, which is produced by patients taking buspirone. Previously, no significant anti-anxiety activity was ever detected for 6-hydroxybuspirone. In consequence, dosing of buspirone was considered optimised when its ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation